Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Heart Failure Drugs: Diuretics

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...

Heart Failure V: Medical Management

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

Heart Failure VI: Adjunct Therapies

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.

Antihypertensive Drugs: Action of Diuretics

Antihypertensive Drugs: Action of Diuretics

Diuretics are antihypertensive drugs used to treat hypertension resulting from sodium and water retention. Sodium, vital for fluid balance and nerve or muscle function, is regulated by the kidneys through millions of nephrons. Blood enters nephrons via afferent arterioles, which branch into capillaries called glomeruli. These filter blood plasma, allowing water and solutes, like sodium ions, to pass through capillary walls into Bowman's capsule. The filtrate then flows through various tubules...

Heart Failure Drugs: β-Blockers

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

AHA/ACC/ESC/WHF Expert Consensus Document: Second Universal Definition of Heart Failure (2026).

Global heart·2026

Same author

A Validated, Modifiable Proteomic Score from the EXSCEL Trial Predicts Cardiovascular Events in Diabetes.

JCI insight·2026

Same author

AHA/ACC/ESC/WHF Expert Consensus Document: Second Universal Definition of Heart Failure (2026).

European heart journal·2026

Same author

AHA/ACC/ESC/WHF Expert Consensus Document: Second Universal Definition of Heart Failure (2026).

Circulation·2026

Same author

AHA/ACC/ESC/WHF Expert Consensus Document: Second Universal Definition of Heart Failure (2026).

Journal of the American College of Cardiology·2026

Same author

A Contemporary Perspective on Acute Decompensated Heart Failure Classification: A State-of-the-art Review from an International Expert Group.

Cardiac failure review·2026

Search research articles

Related Experiment Video

Updated: Jun 18, 2026

Bedside Ultrasound for Guiding Fluid Removal in Patients with Pulmonary Edema: The Reverse-FALLS Protocol

Bedside Ultrasound for Guiding Fluid Removal in Patients with Pulmonary Edema: The Reverse-FALLS Protocol

Published on: July 28, 2018

How to use diuretics in heart failure.

Elizabeth M Volz¹, G Michael Felker

¹Division of Cardiology, Duke University School of Medicine, 2400 Pratt Street, Room 0311 Terrace Level, Durham, NC 27705, USA.

Current Treatment Options in Cardiovascular Medicine

|November 26, 2009

Summary

Diuretic therapy is crucial for managing heart failure congestion but lacks strong evidence for improving outcomes. Reappraisal is needed due to potential harms and emerging alternatives for heart failure symptom management.

Related Experiment Videos

Last Updated: Jun 18, 2026

Bedside Ultrasound for Guiding Fluid Removal in Patients with Pulmonary Edema: The Reverse-FALLS Protocol

Bedside Ultrasound for Guiding Fluid Removal in Patients with Pulmonary Edema: The Reverse-FALLS Protocol

Published on: July 28, 2018

Area of Science:

Cardiology
Pharmacology
Nephrology

Background:

Systemic and pulmonary congestion are hallmarks of heart failure (HF), necessitating diuretic therapy for symptom management.
Despite widespread use, high-quality evidence guiding diuretic use in HF is limited, and they haven't shown mortality benefits like other HF medications.
Observational data suggest potential harm from diuretics in HF, including neurohormonal activation and renal dysfunction.

Purpose of the Study:

To critically re-evaluate the role of diuretic therapy in managing acute and chronic heart failure.
To discuss current diuretic strategies, including loop diuretics, potassium-sparing diuretics, and thiazides, and their limitations.
To explore emerging alternatives and adjuncts to diuretic therapy for heart failure congestion.

Main Methods:

Review of current literature on diuretic use in heart failure management.
Analysis of the pharmacodynamics and clinical application of different diuretic classes.
Discussion of evidence regarding the efficacy and potential adverse effects of diuretics in heart failure.

Main Results:

Loop diuretics are the mainstay for acute and chronic HF congestion, requiring adequate dosing for efficacy.
Strategies for diuretic resistance include dose escalation, continuous infusion, or combination therapy with thiazides.
Aldosterone antagonists are indicated for specific HF patients, primarily for neurohormonal effects, with careful monitoring.

Conclusions:

Diuretics remain essential for symptom control in HF due to congestion, despite limited evidence of survival benefit and potential risks.
Optimal diuretic dosing and judicious use are recommended to minimize adverse effects.
Ongoing trials of novel congestion management strategies may redefine the future of HF therapy.